

CITATION REPORT

List of articles citing

2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult

DOI: 10.1016/j.cjca.2012.11.032

Canadian Journal of Cardiology, 2013, 29, 151-67.

Source: <https://exaly.com/paper-pdf/55859993/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
623	Gender difference in components of metabolic syndrome among patients of type 2 diabetes. 2015 , 31, 886-90		5
622	Protection vasculaire chez les personnes diabétiques. 2013 , 37, S631-S632		
621	Impactful clinical trials of 2012: what clinicians need to know. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 747-50	3.8	1
620	Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1553-68	3.8	126
619	Dyslipidemia. 2013 , 37 Suppl 1, S110-6		13
618	Dyslipidémie. 2013 , 37, S484-S491		1
617	A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. 2013 , 9, 30		493
616	Feedback GAP: pragmatic, cluster-randomized trial of goal setting and action plans to increase the effectiveness of audit and feedback interventions in primary care. 2013 , 8, 142		24
615	Demystifying the management of hypertriglyceridaemia. 2013 , 10, 648-61		75
614	Lipoprotein(a), cardiovascular disease, and contemporary management. 2013 , 88, 1294-311		74
613	Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1395-9	3.8	3
612	Vascular Protection in People with Diabetes. 2013 , 37, S322		
611	Vascular protection in people with diabetes. 2013 , 37 Suppl 1, S100-4		25
610	APOE p.Leu167del mutation in familial hypercholesterolemia. 2013 , 231, 218-22		67
609	High-density lipoprotein and residual cardiovascular risk: De minimis non curat medicus or the COURAGE to be SMART?. 2013 , 62, 1842-4		3
608	A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial. 2013 , 64, 882-9		26
607	Protection vasculaire chez les personnes diabétiques. 2013 , 37, S474-S478		1

606	The necessity for clinical reasoning in the era of evidence-based medicine. 2013 , 88, 1108-14		53
605	Early atherosclerosis detection in asymptomatic patients: a comparison of carotid ultrasound, coronary artery calcium score, and coronary computed tomography angiography. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1687-94	3.8	17
604	The genetic and metabolic determinants of cardiovascular complications in type 2 diabetes: recent insights from animal models and clinical investigations. 2013 , 37, 351-8		4
603	The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 528-42	3.8	147
602	ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management. 2013 , 50, 163-71		14
601	Inequity in primary and secondary preventive care for acute myocardial infarction? Use by socioeconomic status across middle-aged and older patients. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1579-85	3.8	9
600	Statins in patients with chronic kidney disease - an attempt at recommendations. 2013 , 29, 1419-22		9
599	Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. 2013 , 22, 1411-23		18
598	Screening for peripheral arterial disease. 2013 ,		
597	Dyslipidemia prevalence, treatment, control, and awareness in the Canadian Health Measures Survey. 2013 , 104, e252-7		36
596	Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. 2013 , 9, 273-82		5
595	Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US. 2014 , 10, 237-46		9
594	Current guidelines for high-density lipoprotein cholesterol in therapy and future directions. 2014 , 10, 205-16		16
593	High Prevalence of Carotid Plaque Identified Using Standard Carotid Ultrasound Techniques in HIV-Positive Patients with Low to Moderate Vascular Risk. 2014 , 05,		
592	Are the new guidelines for the use of lipid-lowering agents sound, and should their adoption be encouraged?. 2014 , 67, 246-9		3
591	Can I get a guideline to help me interpret treatment guidelines?. 2014 , 67, 181-2		
590	Eficacia y seguridad de la atorvastatina en dosis altas en pacientes con enfermedad renal crónica estadio 5 en terapia de diálisis peritoneal. 2014 , 21, 382-391		
589	Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia. 2014 , 9, 149-161		4

588	A cluster-randomized controlled trial to evaluate the effects of a simplified cardiovascular management program in Tibet, China and Haryana, India: study design and rationale. 2014 , 14, 924	14
587	Update on the NCEP ATP-III emerging cardiometabolic risk factors. 2014 , 12, 115	32
586	Glycated hemoglobin level is significantly associated with the severity of coronary artery disease in non-diabetic adults. 2014 , 13, 181	12
585	Effect of dietary pulse intake on established therapeutic lipid targets for cardiovascular risk reduction: a systematic review and meta-analysis of randomized controlled trials. 2014 , 186, E252-62	111
584	Dairy product consumption has no impact on biomarkers of inflammation among men and women with low-grade systemic inflammation. 2014 , 144, 1760-7	32
583	Development of a Dietary Management Care Map for Metabolic Syndrome. 2014 , 75, 132-9	14
582	Cardiovascular Disease Population Risk Tool (CVDPoRT): predictive algorithm for assessing CVD risk in the community setting. A study protocol. 2014 , 4, e006701	20
581	Clinician's guide to the updated ABCs of cardiovascular disease prevention. 2014 , 3, e001098	17
580	Are we moving towards concordance on the principle that lipid discordance matters?. 2014 , 129, 539-41	18
579	Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. 2014 , 129, 553-61	140
578	New therapies for reducing low-density lipoprotein cholesterol. 2014 , 43, 1007-33	31
577	Lipoprotein(a): an important cardiovascular risk factor and a clinical conundrum. 2014 , 43, 949-62	24
576	Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. 2014 , 37, 195-203	10
575	Doctor my eyes: a statin-cataract connection?. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1508-10	3.8 1
574	Cardiovascular disease in Asian Americans: unmasking heterogeneity. 2014 , 64, 2495-7	8
573	National Lipid Association Annual Summary of Clinical Lipidology 2015. 2014 , 8, S1-36	56
572	Measuring LDL cholesterol: for old and new calculations, is there an optimal formula?. 2014 , 60, 1466-8	5
571	Glycated hemoglobin measurement and prediction of cardiovascular disease. 2014 , 311, 1225-33	136

570	Canadian Cardiovascular Society position statement on familial hypercholesterolemia. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1471-81	3.8	71
569	The clinical burden of type 2 diabetes in patients with acute coronary syndromes: prognosis and implications for short- and long-term management. 2014 , 11, 395-409		11
568	Fructose vs. glucose and metabolism: do the metabolic differences matter?. 2014 , 25, 8-19		38
567	Colesevelam, Ezetimibe, and Patients With Type 2 Diabetes Mellitus: Characteristics and Clinical Outcomes From a Health Care Database. 2014 , 48, 847-855		2
566	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. 2014 , 14, 121		40
565	Efficacy and safety of ezetimibe plus atorvastatin therapy. 2014 , 9, 441-470		5
564	Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities. 2014 , 186, E449-56		25
563	Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB. 2014 , 25, 461-7		43
562	Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society. 2014 , 25, 413-7		2
561	Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. 2014 , 3, e000759		74
560	Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. 2014 , 311, 1870-82		347
559	Low-density lipoprotein cholesterol levels in adults with type 2 diabetes: an alternative equation for accurate estimation and improved cardiovascular risk classification. 2014 , 11, 431-9		6
558	Prevalence of Dyslipidemia and Management in the Thai Population, National Health Examination Survey IV, 2009. 2014 , 2014, 249584		27
557	GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum. 2014 , 2014, 360-6		7
556	Simvastatin/fenofibrate combination in the treatment of dyslipidemia: current evidence. 2014 , 1		
555	Contribution of impaired renal function to cardiovascular risk prediction models in renal transplant recipients. 2014 , 28, 1383-92		3
554	Temas de actualidad en cardiología: riesgo vascular y rehabilitación cardíaca. 2014 , 67, 203-210		11
553	Sex- and gender-related risk factor burden in patients with premature acute coronary syndrome. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 109-17	3.8	43

552	Lipid-lowering therapy in patients 75 years and older: clinical priority or superfluous therapy?. 2014 , 57, 187-96		7
551	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. 2014 , 8, 148-72		79
550	Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines. 2014 , 63, 2789-94		61
549	Risk stratification and selection for statin therapy: going beyond Framingham. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 667-70	3.8	6
548	Are the ACC/AHA guidelines on the treatment of blood cholesterol a game changer? A perspective from the Canadian Cardiovascular Society Dyslipidemia Panel. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 377-80	3.8	24
547	Is plant-based cardioprotection evidence-based?. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1142-4	3.8	
546	Comparison of cardiovascular risk assessment algorithms to determine eligibility for statin therapy: implications for practice in Canada. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 661-6	3.8	7
545	Circulating levels of the vasoactive peptide urotensin II in patients with acute coronary syndrome and stable coronary artery disease. 2014 , 55, 151-7		12
544	Overview of epidemiology and contribution of obesity to cardiovascular disease. 2014 , 56, 369-81		682
543	Cognitive effects of statin medications. 2014 , 28, 411-9		32
542	Screening low-risk individuals for coronary artery disease. 2014 , 16, 402		4
541	Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects \geq 5 years. 2014 , 13, 13		12
540	An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. 2014 , 8, 29-60		246
539	A review on the genetic, environmental, and lifestyle aspects of the early-life origins of cardiovascular disease. 2014 , 44, 54-72		96
538	2013 ACC/AHA cholesterol treatment guideline: what was done well and what could be done better. 2014 , 63, 2674-8		47
537	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. 2014 , 35, 960-8		222
536	Characteristics and evidence-based management of stable coronary artery disease patients in Canada compared with the rest of the world: insights from the CLARIFY registry. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 132-7	3.8	6
535	Dyslipidemias in Kidney Disease. 2014 ,		2

534	Update in cardiology: vascular risk and cardiac rehabilitation. 2014 , 67, 203-10		2
533	Cholesterol, lipoproteins, high-sensitivity c-reactive protein, and other risk factors for atherosclerosis. 2014 , 34, 113-27, vii		24
532	Pharmacogenomics, lipid disorders, and treatment options. 2014 , 96, 36-47		20
531	Problems with modified Framingham Risk Score. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 248.e3	3.8	1
530	High-density lipoprotein mediated cellular cholesterol efflux in acute coronary syndromes. 2014 , 113, 249-55		47
529	Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. 2014 , 237, 829-37		19
528	Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. 2014 , 16, 435		270
527	Guideline-directed low-density lipoprotein management in high-risk patients with ischemic stroke: findings from Get with the Guidelines-Stroke 2003 to 2012. 2014 , 45, 3343-51		24
526	The effect of infrequent low-dose rosuvastatin on the lipid profile. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1392-5	3.8	
525	Screening for peripheral arterial disease. 2014 , CD010835		13
524	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): 2014 update. 2014 , 186, 1299-305		16
523	Review of clinical practice guidelines for the management of LDL-related risk. 2014 , 64, 196-206		43
522	Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes. 2014 , 8, 145-51		13
521	2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. 2014 , 64, 601-12		50
520	2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 129, S49-73		2093
519	Nutrition for the prevention and treatment of chronic kidney disease in diabetes. 2014 , 38, 344-8		19
518	Combination therapy in dyslipidemia: where are we now?. 2014 , 237, 319-35		34
517	Recent advances in pharmacotherapy for hypertriglyceridemia. 2014 , 56, 47-66		104

516	National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. 2014 , 8, 473-88		323
515	2013 ACC/AHA Guideline: a guideline for the population - without evidence from the population. 2014 , 28, 203-4		4
514	Reply to letter from Stern--problem with modifying Framingham Risk Score. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 248.e5	3.8	
513	High-density lipoprotein subfractions: current views and clinical practice applications. 2014 , 25, 329-36		33
512	The 2013 ACC/AHA guidelines on the treatment of blood cholesterol: questions, questions, questions. 2014 , 114, 761-4		15
511	Direct healthcare costs of acute myocardial infarction in Canada—elderly across the continuum of care. 2014 , 3, 44-49		14
510	2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 63, 2935-2959		1625
509	Why global risk scores fail to detect at-risk young women and men with acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 12-3	3.8	1
508	Canadian Journal of Cardiology in 2014: from percutaneous intervention to regenerative medicine. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1-2	3.8	8
507	Canadian Cardiovascular Society position statement on the management of thoracic aortic disease. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 577-89	3.8	135
506	ICEBERG: Intimal Carotid Evaluation Before Echocardiography Reveals Global Vascular Risk. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1183-9	3.8	1
505	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. 2014 , 171, 309-25		251
504	Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. 2014 , 2, 455-63		68
503	A randomized controlled trial of electroacupuncture at body acupoints and Fenglong for regulating serum lipids in dyslipidemic patients in Thailand. 2014 , 20, 26-31		3
502	Implementing phytosterols into medical practice as a cholesterol-lowering strategy: overview of efficacy, effectiveness, and safety. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 1225-32	3.8	58
501	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. 2014 , 2, 655-66		357
500	C-reactive protein and hypertension. 2014 , 28, 410-5		95
499	Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 837-49	3.8	97

498	The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. 2014 , 15, 1-15	62
497	Achievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: Results from VOYAGER. 2014 , 5, 61-66	1
496	Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. 2014 , 78, 1073-82	87
495	Concepts and controversies: the 2013 American College of Cardiology/American Heart Association risk assessment and cholesterol treatment guidelines. 2014 , 160, 356-8	38
494	Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies. 2014 , 37, 597-604	36
493	Managing Menopause Chapter 1 Assessment and Risk Management of Menopausal Women. 2014 , 36, S6-S15	1
492	Clinician's Commentary on Li et al.(1.). 2014 , 66, 197-8	
491	Nuts and CVD. 2015 , 113 Suppl 2, S111-20	100
490	Nutrition attributes and health effects of pistachio nuts. 2015 , 113 Suppl 2, S79-93	69
489	Clinical lipidology: A subspecialty whose time has come. 2015 , 9, 634-9	2
488	Quantifying the impact of using Coronary Artery Calcium Score for risk categorization instead of Framingham Score or European Heart SCORE in lipid lowering algorithms in a Middle Eastern population. 2015 , 27, 234-43	
487	The hypertriglyceridemic-waist phenotype is associated with the Framingham risk score and subclinical atherosclerosis in Canadian Cree. 2015 , 25, 1050-5	7
486	Validity of Self-Report of Cardiovascular Risk Factors in a Population at High Risk for Stroke. 2015 , 24, 2860-5	30
485	Unintentional Discontinuation of Chronic Medications for Seniors in Nursing Homes: Evaluation of a National Medication Reconciliation Accreditation Requirement Using a Population-Based Cohort Study. 2015 , 94, e899	2
484	Do we need a disease-specific cardiovascular risk calculator for patients with rheumatoid arthritis?. 2015 , 67, 1990-4	8
483	GPs' perspectives on secondary cardiovascular prevention in older age: a focus group study in the Netherlands. 2015 , 65, e739-47	16
482	2015 Meet-The-Professor: Endocrine Case Management. 2015 ,	
481	Risk scoring for the primary prevention of cardiovascular disease. 2015 ,	3

480	Lifestyle Factors and Coronary Artery Calcification. 2014 , 2, 95-102	6
479	Descriptive data on cardiovascular and metabolic risk factors in ambulatory and non-ambulatory adults with cerebral palsy. 2015 , 5, 967-70	11
478	A cluster-randomized controlled knowledge translation feasibility study in Alberta community pharmacies using the PARIHS framework: study protocol. 2015 , 1, 2	1
477	Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. 2015 , 14, 57	18
476	Rationale, design and baseline characteristics of a randomized controlled trial of a web-based computer-tailored physical activity intervention for adults from Quebec City. 2015 , 15, 1038	6
475	New worldwide lipid guidelines. 2015 , 30, 447-53	2
474	First-episode affective psychosis and lipid monitoring: survival analysis of the first abnormal lipid test. 2015 , 9, 507-11	3
473	Sex Differences in the Impact of the Mediterranean Diet on LDL Particle Size Distribution and Oxidation. 2015 , 7, 3705-23	16
472	Combination pharmacotherapy in lipid management. 2015 , 58, 745	
471	Evaluating of Physiological Chemical Levels in Blood to Assess the Risk of Morbidity and Mortality of Ischemic Cardiovascular Disease. 2015 , 12, 11549-59	0
470	The Importance of Caveolin-1 as Key-Regulator of Three-Dimensional Growth in Thyroid Cancer Cells Cultured under Real and Simulated Microgravity Conditions. 2015 , 16, 28296-310	30
469	Feasibility of Recruiting Families into a Heart Disease Prevention Program Based on Dietary Patterns. 2015 , 7, 7042-57	7
468	Cardiovascular risk prediction: balancing complexity against simple practicality. 2015 , 65, 4-5	2
467	Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. 2015 , 14, 45	11
466	A Comparison of Accelerometer Cut-Points among Individuals with Coronary Artery Disease. <i>PLoS ONE</i> , 2015 , 10, e0137759	3-7 20
465	The Canadian Cardiac Rehabilitation Registry: Inaugural Report on the Status of Cardiac Rehabilitation in Canada. 2015 , 2015, 278979	10
464	The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada. 2015 , 2015, 820403	26
463	Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice. 2015 , 9, 923-35	8

462	Niacin as antidiyslipidemic drug. 2015 , 93, 1043-54	20
461	Lipid Management in Diabetes with a Focus on Emerging Therapies. 2015 , 39 Suppl 5, S183-90	7
460	Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV. 2015 , 31, 276-81	5
459	Comparing Guidelines for Statin Treatment in Canada and the United States. 2015 , 4,	7
458	Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. 2015 , 37, 2732-50	6
457	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. 2015 , 9, S1-122.e1	293
456	Is HPS2-THRIVE the death knell for niacin?. 2015 , 9, 343-50	8
455	Is the Guideline Process Replicable and, if Not, What Does This Mean?. 2015 , 58, 3-9	2
454	Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease. 2015 , 4, e001675	17
453	Comparative effectiveness of cardioprotective drugs in elderly individuals with type 2 diabetes. 2015 , 69, 305-12	1
452	Management of lipid disorders in patients living with HIV. 2015 , 55, 957-74	26
451	ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. 2015 , 11, 27-37	45
450	Lipid Lowering Drugs. 2015 , 915-929	
449	The Cardiovascular Health in Ambulatory Care Research Team (CANHEART): using big data to measure and improve cardiovascular health and healthcare services. 2015 , 8, 204-12	96
448	[2013 Guidelines ACC/AHA cardiovascular risk. Incomplete evidence and failed attempt at simplification]. 2015 , 27, 74-9	
447	Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists. 2015 , 148, 21-8	4
446	Screening Strategies and Primary Prevention Interventions in Relatives of People With Coronary Artery Disease: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 649-57 ^{3.8}	6
445	New-onset diabetes and statins: throw the bath water out, but, please, keep the baby!. 2015 , 64, 471-5	19

444	Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. 2015 , 240, 482-9		17
443	Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy. 2015 , 13, 1059-66		4
442	Incident Diabetes With Statins: Biology, Artifact, or Both?. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 963-5.8		3
441	Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010. 2015 , 9, 525-32		28
440	Successful reintroduction of statin therapy after statin-associated rhabdomyolysis. 2015 , 9, 594-6		5
439	Metabolic Syndrome Sinkholes: What to Do When Occam's Razor Gets Blunted. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 601-4	3.8	3
438	New Hope for Lipid-Lowering Beyond Statins: Effect of IMPROVE-IT on Understanding and Implementation of Atherosclerosis Prevention. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 585-7	3.8	7
437	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol: The Very Large Database of Lipids Study (VLDL-2B). 2015 , 132, 667-76		28
436	Primary prevention of cardiovascular disease: global cardiovascular risk assessment and management in clinical practice. 2015 , 1, 31-36		5
435	The new pooled cohort equations risk calculator. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 613-9	3.8	52
434	Alternativas terapéuticas al manejo farmacológico con estatinas en adultos con dislipidemia. Revisión sistemática de la literatura y recomendaciones generales. 2015 , 22, 179-186		1
433	A Randomized Double-blind Controlled Trial of Lactobacillus acidophilus Plus Bifidobacterium bifidum versus Placebo in Patients with Hypercholesterolemia. 2015 , 9, KC01-4		20
432	Cardiology patient page. Statin intolerance. 2015 , 131, e389-91		41
431	Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. 2015 , 100, 3140-8		176
430	A Cluster-Randomized, Controlled Trial of a Simplified Multifaceted Management Program for Individuals at High Cardiovascular Risk (SimCard Trial) in Rural Tibet, China, and Haryana, India. 2015 , 132, 815-24		90
429	Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. 2015 , 9, 295-304		90
428	Association and interaction of PPAR α and β gene polymorphisms with low-density lipoprotein-cholesterol in a Chinese Han population. 2015 , 19, 379-86		15
427	Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. 2015 , 61, 1156-63		38

426	Primary prevention: do the very elderly require a different approach?. 2015 , 25, 228-39	15
425	Clinical guidelines on hyperlipidaemia: recent developments, future challenges and the need for an Australian review. 2015 , 24, 495-502	0
424	Tools for Cardiovascular Risk Assessment in Clinical Practice. 2015 , 9, 1	
423	Deeper insight into chronic kidney disease-related atherosclerosis: comparative proteomic studies of blood plasma using 2DE and mass spectrometry. 2015 , 13, 20	20
422	Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. 2015 , 372, 1500-9	1081
421	Sex differences in the impact of the Mediterranean diet on systemic inflammation. 2015 , 14, 46	22
420	Cardiac testing in an asymptomatic 42-year-old man. 2015 , 187, 747-749	
419	Lipid management in human immunodeficiency virus. 2015 , 33, 277-98	1
418	Targeting lipoprotein (a): an evolving therapeutic landscape. 2015 , 17, 502	7
417	Common low-density lipoprotein receptor p.G116S variant has a large effect on plasma low-density lipoprotein cholesterol in circumpolar inuit populations. 2015 , 8, 100-5	7
416	National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. 2015 , 9, 129-69	478
415	Medical Management of Serum Lipids and Coronary Heart Disease. 2015 , 39-55	
414	Physical activity prescriptions in healthy populations: resources for Canadian nurse practitioners. 2015 , 40, 45-54	1
413	Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge. 2015 , 47, 805-13	10
412	Cardiovascular Imaging for the Primary Prevention of Atherosclerotic Cardiovascular Disease Events. 2015 , 8, 36	21
411	Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. 2015 , 15, 715-27	4
410	Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council. 2015 , 35, 2269-80	48
409	Early life adversity and C-reactive protein in diverse populations of older adults: a cross-sectional analysis from the International Mobility in Aging Study (IMIAS). 2015 , 15, 102	17

408	Inappropriate repeats of six common tests in a Canadian city: a population cohort study within a laboratory informatics framework. 2015 , 144, 704-12		38
407	Effects of Vegetarian Diets on Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2015 , 4, e002408		144
406	The effect of a dietary portfolio compared to a DASH-type diet on blood pressure. 2015 , 25, 1132-9		28
405	Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia. 2015 , 102, 168-75		4
404	If not dieting, how to lose weight? Tips and tricks for a better global and cardiovascular health. 2015 , 127, 173-85		2
403	Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy. 2015 , 31, 2273-85		6
402	Predicted 10-year risk of cardiovascular disease among Canadian adults using modified Framingham Risk Score in association with dietary intake. 2015 , 40, 1068-74		7
401	Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines. 2015 , 90, 1262-71		15
400	Perspectives on Cholesterol Guidelines. 2015 , 313-327		
399	Are Statins out in the COLD? The STATCOPE Trial. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 970-3	3.8	4
398	Online clinical pathway for managing adults with chronic kidney disease. 2015 , 148, 257-62		9
397	LDL cholesterol, statins and PCSK 9 inhibitors. 2015 , 67, 419-24		10
396	Acute kidney injury: preclinical innovations, challenges, and opportunities for translation. 2015 , 2, 30		20
395	"Fleshing Out" the Benefits of Adopting a Vegetarian Diet. 2015 , 4, e002654		2
394	Providing optimal regional care for ST-segment elevation myocardial infarction: a prospective cohort study of patients in the Hamilton Niagara Haldimand Brant Local Health Integration Network. 2015 , 3, E1-7		10
393	Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). 2015 , 9, 377-83		32
392	Cardiovascular risk and white matter lesions after endocrine control of Cushing's syndrome. 2015 , 173, 765-75		29
391	2013 ACC/AHA cholesterol treatment guideline: Paradigm shifts in managing atherosclerotic cardiovascular disease risk. 2015 , 25, 340-7		17

390	Inflammation modulation and cardiovascular disease prevention. 2015 , 22, 719-33	40
389	The new dyslipidemia guidelines: what is the debate?. <i>Canadian Journal of Cardiology</i> , 2015 , 31, 605-12 3.8	32
388	Best practices for cardiovascular disease prevention in rheumatoid arthritis: a systematic review of guideline recommendations and quality indicators. 2015 , 67, 169-79	36
387	Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review. 2016 , 1, 214-229	25
386	Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders. 2016 , 12, 421-433	7
385	New Antilipid Drugs: Do the Known Benefits Justify the Expense?. 2016 , 69, 323-6	
384	EFFICACY AND SAFETY OF LIPID-LOWERING DRUGS IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE ELDERLY. 2016 , 12, 351-358	
383	Cholesterol testing among men and women with disability: the role of morbidity. 2016 , 8, 313-21	2
382	Vascular Pathobiology. 2016 , 85-124	6
381	Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk. 2016 , 22, 685-98	43
380	PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. 2016 , 12, 185-97	11
379	Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. 2016 , 15, 8-14	21
378	Sex Differences in the Effects of Repeated Taste Exposure to the Mediterranean Diet: A 6-month Follow-up Study. 2016 , 77, 125-32	1
377	Residual cardiovascular risk in patients who received lipid-lowering treatment in a real-life setting: retrospective study. 2016 , 8, 649-655	10
376	Current status of carotid ultrasound in atherosclerosis. 2016 , 6, 285-96	22
375	Disorders of Lipid Metabolism. 2016 , 1660-1700	4
374	High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities. 2016 , 71, 235-42	54
373	Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. 2016 , 8, 201-10	31

372	Low-glycaemic index diet to improve glycaemic control and cardiovascular disease in type 2 diabetes: design and methods for a randomised, controlled, clinical trial. 2016 , 6, e012220		3
371	Should apolipoprotein B replace LDL cholesterol as therapeutic targets are lowered?. 2016 , 27, 359-66		10
370	Carotid IMT is more associated with stroke than risk calculators. 2016 , 133, 442-50		6
369	Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events. 2016 , 118, 647-55		17
368	Rationale and design of the multidisciplinary team InterventIOn in cArdio-oNcology study (TITAN). 2016 , 16, 733		26
367	Glycosylated haemoglobin as a predictor of cardiovascular events and mortality: a protocol for a systematic review and meta-analysis. 2016 , 6, e012229		7
366	Nutritional management of hyperapoB. 2016 , 29, 202-233		16
365	The effect of oat β -glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials. 2016 , 116, 1369-1382		124
364	The future of lipid guidelines. 2016 , 27, 585-591		2
363	Comprehensive Analysis of Established Dyslipidemia-Associated Loci in the Diabetes Prevention Program. 2016 , 9, 495-503		3
362	A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessment. 2016 , 10, 228-39		4
361	Provider understanding of the 2013 ACC/AHA cholesterol guideline. 2016 , 10, 497-504.e4		54
360	Applying Atherosclerotic Risk Prevention Guidelines to Elderly Patients: A Bridge Too Far?. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 598-602	3.8	1
359	Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. 2016 , 244, 138-46		150
358	Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD. 2016 , 67, 965-77		15
357	The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled Rx EACH Trial. 2016 , 67, 2846-54		107
356	Common Variants in Cholesterol Synthesis- and Transport-Related Genes Associate with Circulating Cholesterol Responses to Intakes of Conventional Dairy Products in Healthy Individuals. 2016 , 146, 1008-16		8
355	Statin combination therapy and cardiovascular risk reduction. 2016 , 12, 289-315		9

354	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016 , 32, S15-34	3.8	7
353	Lower might be better - It matters how you get there, and in whom. 2016 , 37, 1380-3		8
352	Recent Update to the US Cholesterol Treatment Guidelines: A Comparison With International Guidelines. 2016 , 133, 1795-806		69
351	The 2013 cholesterol guideline controversy: Would better evidence prevent pharmaceuticalization?. 2016 , 120, 797-808		8
350	Factores sociolaborales asociados al riesgo cardiovascular según el score de Framingham en trabajadores de Lima, 2015. 2016 , 53, 84-89		
349	Tratamiento de la diabetes mellitus (I). 2016 , 12, 1001-1012		0
348	Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients. 2016 , 10, 1212-22		42
347	Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population. 2016 , 32, 1955-1958		
346	Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. 2016 , 225, 184-196		110
345	Statin Intolerance: A Literature Review and Management Strategies. 2016 , 59, 153-164		49
344	Cholesterol Guidelines: More Similar Than Different. 2016 , 59, 190-199		2
343	Gaps in Addressing Cardiovascular Risk in Rheumatoid Arthritis: Assessing Performance Using Cardiovascular Quality Indicators. 2016 , 43, 1965-1973		17
342	Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia. 2016 , 59, 165-171		9
341	Statin Use and Its Facility-Level Variation in Patients With Diabetes: Insight From the Veterans Affairs National Database. 2016 , 39, 185-91		31
340	Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk. 2016 , 23, 217-30		18
339	Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis. 2016 , 5, 541-547		4
338	Comprehensive Review of the Impact of Dairy Foods and Dairy Fat on Cardiometabolic Risk. 2016 , 7, 1041-1051		85
337	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. 2016 , 30, 473-483		125

336	Non-HDL-C is a Better Predictor for the Severity of Coronary Atherosclerosis Compared with LDL-C. 2016 , 25, 975-81	30
335	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1263-1282 ^{3.8}	543
334	Non-HDL-C vs. LDL-C in Predicting the Severity of Coronary Atherosclerosis. 2016 , 25, 953-4	9
333	Nuts and their co-products: The impact of processing (roasting) on phenolics, bioavailability, and health benefits [A comprehensive review. 2016 , 26, 88-122	95
332	Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. 2016 , 316, 1997-2007	343
331	Onset of Impaired Sleep and Cardiovascular Disease Risk Factors: A Longitudinal Study. 2016 , 39, 1709-18	41
330	Development and implementation of an online clinical pathway for adult chronic kidney disease in primary care: a mixed methods study. 2016 , 16, 109	13
329	EXercise to prevent AnthrCycline-based Cardio-Toxicity (EXACT) in individuals with breast or hematological cancers: a feasibility study protocol. 2016 , 2, 44	10
328	A systematic review and meta-analysis of randomized controlled trials of the effect of barley β -glucan on LDL-C, non-HDL-C and apoB for cardiovascular disease risk reduction. 2016 , 70, 1239-1245	37
327	Lipoprotein (a), an independent cardiovascular risk marker. 2016 , 2, 7	18
326	Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. 2016 , 65, 1767-78	104
325	A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA (ComparED) Study. 2016 , 104, 280-7	142
324	LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design. 2016 , 10, 273-82	27
323	Lipid Management Guidelines from the Departments of Veteran Affairs and Defense: A Critique. 2016 , 129, 906-12	5
322	Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. 2016 , 16, 74	18
321	The OPTIMIZE trial: Rationale and design of a randomized controlled trial of motivational enhancement therapy to improve adherence to statin medication. 2016 , 49, 47-56	1
320	Vascular age to determine cardiovascular disease risk: A systematic review of its concepts, definitions, and clinical applications. 2016 , 23, 264-74	69
319	Community pharmacist targeted screening for chronic kidney disease. 2016 , 149, 13-7	13

318	Improving the Monitoring and Care of Patients With Familial Hypercholesterolemia. 2016 , 67, 1286-8		6
317	Potential Immunomodulatory Effects of Statins in Inflammatory Bowel Disease. 2016 , 22, 724-32		32
316	Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). 2016 , 12, 468-495		36
315	Lipid Management in Human Immunodeficiency Virus. 2016 , 45, 141-69		5
314	A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. 2016 , 10, 240-64		3
313	Prevention, Detection, and Management of Chemotherapy-Related Cardiac Dysfunction. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 891-9	3.8	13
312	Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. 2016 , 37, 1373-9		125
311	Cardiac Outcomes in Survivors of Pediatric and Adult Cancers. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 871-80	3.8	23
310	[The role of atherogenic dyslipidaemia in clinical practice guidelines]. 2016 , 28, 65-70		9
309	Coronary Artery Disease in French Canadians-Investigation of a Suggested Vulnerable Population. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1240-1245	3.8	1
308	National Lipid Association Annual Summary of Clinical Lipidology 2016. 2016 , 10, S1-43		74
307	Dyslipidemia in systemic lupus erythematosus: just another comorbidity?. 2016 , 45, 604-10		56
306	Evidence, Guidelines, and Gut Checks: Musings on Entering the Post-Statins Era of Lipid Management. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 271-4	3.8	1
305	A link between hypercholesterolemia and chronic lymphocytic leukemia. 2016 , 57, 797-802		13
304	Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives. 2016 , 16, 1-8		14
303	Clinical Treatment of Vascular Diseases. 2017 , 233-251		
302	Genetics for the Identification of Lipid Targets Beyond PCSK9. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 334-342	3.8	7
301	Functional foods and dietary supplements for the management of dyslipidaemia. 2017 , 13, 278-288		110

300 Cardiac Effects of Antirheumatic Drugs. **2017**, 14, 489-529

299 Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. **2017**, 69, 458-463 61

298 Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. **2017**, 63, 870-879 47

297 Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: protocol for an overview of systematic reviews. **2017**, 7, e014206 7

296 Nutrition Intervention on Cardiovascular Risk Factors in Healthy Individuals: Glass Half Empty or Half Full?. **2017**, 69, 1113-1115 3

295 Management Strategies for Statin-Associated Muscle Symptoms: How Useful Is Same-Statins Rechallenge?. *Canadian Journal of Cardiology*, **2017**, 33, 666-673 3.8 1

294 Effect of Current Dietary Recommendations on Weight Loss and Cardiovascular Risk Factors. **2017**, 69, 1103-1112 24

293 Can pulses play a role in improving cardiometabolic health? Evidence from systematic reviews and meta-analyses. **2017**, 1392, 43-57 39

292 Association between neighbourhood walkability and metabolic risk factors influenced by physical activity: a cross-sectional study of adults in Toronto, Canada. **2017**, 7, e013889 28

291 Use of cardiovascular age for assessing risks and benefits of menopausal hormone therapy. **2017**, 24, 589-595 8

290 The Cardiovascular Health in Ambulatory Care Research Team performance indicators for the primary prevention of cardiovascular disease: a modified Delphi panel study. **2017**, 5, E315-E321 4

289 Metabolic outcomes of bergamot polyphenolic fraction administration in patients treated with second-generation antipsychotics: a pilot study. **2017**, 40, 32-35 9

288 Lipoprotein(a): A Lipoprotein Whose Time Has Come. **2017**, 19, 48 9

287 Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care. **2017**, 263, 36-41 39

286 Interaction of Serum Phosphate with Age as Predictors of Cardiovascular Risk Scores in Stable Renal Transplant Recipients. **2017**, 26, 102-108 2

285 Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical Practice. **2017**, 101, 689-699 31

284 Community Pharmacy-Based Inducement Programs Associated With Better Medication Adherence: A Cohort Study. **2017**, 51, 630-639 3

283 The Effect of Triglyceride Concentration on Attainment of Lipid Targets in Patients with Diabetes. **2017**, 41, 380-384 2

282	A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B. 2017 , 105, 1239-1247	43
281	Chemical composition of pine nut (<i>Pinus pinea</i> L.) grown in three geographical macrozones in Chile. 2017 , 15, 284-290	19
280	Characterization of Guideline Evidence for Off-label Medication Use in the Intensive Care Unit. 2017 , 51, 529-542	2
279	Usefulness of non-fasting lipid parameters in children. 2017 , 30, 77-83	7
278	Effects of tetramethylpyrazine from Chinese black vinegar on antioxidant and hypolipidemia activities in HepG2 cells. 2017 , 109, 930-940	29
277	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. 2017 , 22, 1-26	31
276	How dietary evidence for the prevention and treatment of CVD is translated into practice in those with or at high risk of CVD: a systematic review. 2017 , 20, 30-45	3
275	Vascular Diseases for the Non-Specialist. 2017 ,	3
274	Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ) [®] . 2017 , 10, 321-334	9
273	microRNAs in lipoprotein and lipid metabolism: from biological function to clinical application. 2017 , 55, 667-686	24
272	Trans-Fatty Acids and Cardiovascular Disease: Urgent Need for Legislation. 2017 , 138, 254-258	23
271	Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease. 2017 , 129, 801-810	1
270	Optimal Target Level of Low-density Lipoprotein Cholesterol for Vascular Function in Statin Naïve Individuals. 2017 , 7, 8422	9
269	Physical Health and Drug Safety in Individuals with Schizophrenia. 2017 , 62, 673-683	16
268	An Evaluation of FrancoForme: A CASE-MANAGED HOME-BASED PRIMARY AND SECONDARY CARDIOVASCULAR DISEASE PREVENTION PROGRAM FOR FRENCH-SPEAKING CANADIANS. 2017 , 37, 437-444	2
267	Cardiac Rehabilitation Outcomes by Ethnocultural Background: RESULTS FROM THE CANADIAN CARDIAC REHAB REGISTRY. 2017 , 37, 334-340	0
266	Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis. 2017 , 7, e015949	81
265	Statins and Cardiovascular Health: Controversy, Consensus, and Clinical Judgment. 2017 , 32, 90-92	

264	Cardiovascular Risk Prevention in a Canadian Population of Patients with Giant Cell Arteritis. 2017 , 44, 1942-1943		
263	Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention. 2017 , 92, 1831-1841		22
262	What is sufficient drug therapy for lipoprotein elevations?. 2017 , 11, 1300-1308		
261	Protocol for the HAPPY Hearts study: cardiovascular screening for the early detection of future adverse cardiovascular outcomes in middle-aged and older women: a prospective, observational cohort study. 2017 , 7, e018249		10
260	Accuracy of low-density lipoprotein cholesterol estimation at very low levels. 2017 , 15, 83		26
259	Hypercholesterolaemia and vascular dementia. 2017 , 131, 1561-1578		65
258	A systematic review of the effect of yogurt consumption on chronic diseases risk markers in adults. 2017 , 56, 1375-1392		19
257	Dyslipidemias. 2017 , 1637-1647		
256	Preoperative Optimization of the Heart Failure Patient Undergoing Cardiac Surgery. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 72-79	3.8	19
255	Handbook of Cardiovascular Disease Management in Rheumatoid Arthritis. 2017 ,		1
254	Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 385-392	3.8	17
253	Cardiovascular Risk Factor Management Performance in Canada and the United States: A Systematic Review. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 393-404	3.8	18
252	Brain Function Is Linked to LDL Cholesterol in Older Adults with Cardiovascular Risk. 2017 , 65, e51-e55		8
251	Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin. 2017 , 21, 95-105		9
250	Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system. 2017 , 11, 70-79.e1		28
249	Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat. 2017 , 24, 76-83		22
248	Effect of Plant Protein on Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2017 , 6,		46
247	Erectile Dysfunction Medications and Treatment for Cardiometabolic Risk Factors: A Pharmacoepidemiologic Study. 2017 , 14, 1597-1605		4

246	Use of Healthcare Services by Patients with Non-Communicable Diseases in Nepal: A Qualitative Study with Healthcare Providers. 2017 , 11, LC01-LC05	3
245	Dietary Approaches in the Management of Diabetic Patients with Kidney Disease. 2017 , 9,	49
244	The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population. 2017 , 24, e348-e353	17
243	Knowledge, attitude and practice of community pharmacists in relation to cholesterol screening in Delta State, Nigeria. 2017 , 11, 451-457	
242	High prevalence of dyslipidemia among primary care patients with hypertension and diabetes in Jamaica. 2017 , 2, e61-e67	4
241	Effects of a 12-week cardiovascular rehabilitation programme on systemic inflammation and traditional coronary artery disease risk factors in patients with rheumatoid arthritis (CARDIA trial): a randomised controlled trial. 2017 , 7, e018540	2
240	Morphometric and chemical fruit variability of selected stone pine trees (<i>Pinus pinea</i> L.) grown in non-native environments. 2018 , 152, 547-555	10
239	Effect of pasta in the context of low-glycaemic index dietary patterns on body weight and markers of adiposity: a systematic review and meta-analysis of randomised controlled trials in adults. 2018 , 8, e019438	31
238	Dyslipidemia. 2018 , 42 Suppl 1, S178-S185	26
237	Managing premature atherosclerosis in patients with chronic inflammatory diseases. 2018 , 190, E430-E439	3
236	A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention. 2018 , 22, 241-254	6
235	Update on the laboratory investigation of dyslipidemias. 2018 , 479, 103-125	29
234	β-glucans and cholesterol (Review). 2018 , 41, 1799-1808	45
233	Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. 2018 , 45, 378-384	27
232	Beneficial effects of consumption of acerola, cashew or guava processing by-products on intestinal health and lipid metabolism in dyslipidaemic female Wistar rats. 2018 , 119, 30-41	33
231	Validation of the Friedewald formula for the estimation of low density lipoprotein cholesterol in a sub-Saharan African population. 2018 , 53, 25-30	5
230	The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22. 2018 , 41, 68-73	3
229	Nutritional potential, chemical profile and antioxidant activity of Chichí (<i>Sterculia striata</i>) nuts and its by-products. 2018 , 106, 736-744	11

228	Effectiveness of a Type 2 Diabetes Screening Intervention in the Canadian Workplace. 2018 , 42, 493-499.e1	3
227	Lipid profile and dyslipidemia among school-age children in urban Ghana. 2018 , 18, 320	6
226	New diet trials and cardiovascular risk. 2018 , 33, 423-428	4
225	Red Yeast Rice (RYR) supplementation in patients treated with second-generation antipsychotics. 2018 , 37, 167-171	5
224	Cardiovascular disease risk in individuals with chronic spinal cord injury: Prevalence of untreated risk factors and poor adherence to treatment guidelines. 2018 , 41, 2-9	14
223	Cardiovascular risk management in rheumatoid arthritis: A large gap to close. 2018 , 16, 152-157	7
222	Women's Heart Health: Knowledge, Beliefs, and Practices of Canadian Physicians. 2018 , 27, 72-82	8
221	MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?. 2018 , 54, 224-233	21
220	Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey. 2018 , 42, 130-137	8
219	Need for hyperlipidemia management policy reform in China: learning from the global experience. 2018 , 34, 197-207	1
218	Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein Versus Double Atorvastatin Dose in Egyptian Diabetic Patients. 2018 , 58, 34-41	3
217	Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled REACH Trial. 2018 , 71, 42-51	13
216	Antihyperglycemic Agents Are Inversely Associated With Intracranial Aneurysm Rupture. 2018 , 49, 34-39	8
215	Dialogue between primary and secondary health care providers in a Brazilian hypertensive population. 2018 , 64, 799-805	1
214	Lipid Measurements. 2018 , 88-97	
213	Screening for Atherosclerotic Cardiovascular Disease in Asymptomatic Individuals. 2018 , 459-478	2
212	Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia. 2018 , 39, 697-704	3
211	Nonfasting lipid testing: the new standard for cardiovascular risk assessment. 2018 , 190, E1317-E1318	5

210	General practitioners' perspectives on the prevention of cardiovascular disease: systematic review and thematic synthesis of qualitative studies. 2018 , 8, e021137	10
209	Heritability and Genome-Wide Association Study of Plasma Cholesterol in Chinese Adult Twins. 2018 , 9, 677	9
208	Emergency Medical Services Utilization and Outcomes of Patients with ST-Elevation Myocardial Infarction in Lebanon. 2018 , 55, 827-835	1
207	A Randomized Controlled Trial to Compare the Effect of Peanuts and Almonds on the Cardio-Metabolic and Inflammatory Parameters in Patients with Type 2 Diabetes Mellitus. 2018 , 10,	32
206	Genetic and Common Environmental Contributions to Familial Resemblances in Plasma Carotenoid Concentrations in Healthy Families. 2018 , 10,	6
205	Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe. 2018 , 25, 1966-1976	30
204	Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk. 2018 , 22, 641-652	1
203	Effect of psyllium (<i>Plantago ovata</i>) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. 2018 , 108, 922-932	19
202	Nuts as a replacement for carbohydrates in the diabetic diet: a reanalysis of a randomised controlled trial. 2018 , 61, 1734-1747	15
201	Validity of a Novel Method for Estimating Low-Density Lipoprotein Cholesterol Levels in Cardiovascular Disease Patients Treated with Statins. 2018 , 25, 643-652	11
200	Performance of LDL-C calculated with Martin's formula compared to the Friedewald equation in familial combined hyperlipidemia. 2018 , 277, 204-210	25
199	Quality of care for cardiovascular disease prevention in rheumatoid arthritis: compliance with hyperlipidemia screening guidelines. 2018 , 57, 1789-1794	9
198	Hypercholesterolaemia - practical information for non-specialists. 2018 , 14, 1-21	30
197	Improvement of the Functional and Healthy Properties of Meat Products. 2018 , 1-74	10
196	Coreopsis Tinctoria Modulates Lipid Metabolism by Decreasing Low-Density Lipoprotein and Improving Gut Microbiota. 2018 , 48, 1060-1074	5
195	Risk evaluation of new-onset atrial fibrillation complicating ST-segment elevation myocardial infarction: a comparison between GRACE and CHADS-VASc scores. 2018 , 13, 1099-1109	4
194	Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement. 2018 , 320, 272-280	63
193	Ezetimibe prescriptions in older Canadian adults after an acute myocardial infarction: a population-based cohort study. 2018 , 17, 8	6

192	FIT for FUNCTION: study protocol for a randomized controlled trial. 2018 , 19, 39	5
191	Non-fasting versus fasting cholesterol measurement. 2018 , 43, 16-20	1
190	Assessment of cardiovascular risk and preparticipation screening protocols in masters athletes: the Masters Athlete Screening Study (MASS): a cross-sectional study. 2018 , 4, e000370	12
189	Comparing the Consistency and Performance of Various Coronary Heart Disease Prediction Models for Primary Prevention Using a National Representative Cohort in Taiwan. 2018 , 82, 1805-1812	3
188	Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. 2019 ,	25
187	Homocysteine and education but not lipoprotein (a) predict estimated 10-year risk of cardiovascular disease in blood donors: a community based cross-sectional study. 2019 , 19, 177	1
186	Chapitre 1 : Évaluation et gestion des risques chez les femmes ménopausées. 2019 , 41 Suppl 1, S36-S48	
185	Association Between Neighborhood Walkability and Predicted 10-Year Cardiovascular Disease Risk: The CANHEART (Cardiovascular Health in Ambulatory Care Research Team) Cohort. 2019 , 8, e013146	23
184	Au-delà du risque cardiovasculaire : le rôle des lipoprotéines contenant l'apoB athérogènes dans l'étiologie du diabète de type 2. 2019 , 13, 129-139	2
183	Cardiovascular Protective Effects of Centella asiatica and Its Triterpenes: A Review. 2019 , 85, 1203-1215	25
182	Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. 2019 , 18, 134	21
181	Milk and Dairy Product Consumption and Cardiovascular Diseases: An Overview of Systematic Reviews and Meta-Analyses. 2019 , 10, S164-S189	47
180	Role of Functional Fortified Dairy Products in Cardiometabolic Health: A Systematic Review and Meta-analyses of Randomized Clinical Trials. 2019 , 10, S251-S271	11
179	A Meta-Analysis of 46 Studies Identified by the FDA Demonstrates that Soy Protein Decreases Circulating LDL and Total Cholesterol Concentrations in Adults. 2019 , 149, 968-981	36
178	Pre-participation Evaluation in Sports Practice. 2019 , 13-25	1
177	Effect of carotid image-based phenotypes on cardiovascular risk calculator: AECRS1.0. 2019 , 57, 1553-1566	27
176	PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab. 2019 , 13, 443-454	2
175	Diagnosis and Management of Dyslipidemia. 2019 , 23-45	

174	Cardiovascular Risk: Assumptions, Limitations, and Research. 2019 , 201-266		
173	Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 644-652	3.8	0
172	Cardiovascular Care in Patients With HIV. 2019 ,		1
171	Drugs for Treatment of Dyslipidemia Available in the USA. 2019 , 171-195		
170	Measuring Cardiovascular Quality in Primary Care Using Canadian Cardiovascular Harmonization of National Guidelines Endeavour and Electronic Medical Record Data in Ontario. 2019 , 1, 1-9		1
169	Lipoprotein(a) and Risk of Ischemic Stroke in the REGARDS Study. 2019 , 39, 810-818		25
168	Cardiovascular Risk Assessment and Follow-Up of Women After Hypertensive Disorders of Pregnancy:A Prospective Cohort Study. 2019 , 41, 1157-1167.e1		9
167	Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events. 2019 , 289, 138-143		8
166	Performance of atherosclerotic cardiovascular risk prediction models in a rural Northern Chinese population: Results from the Fangshan Cohort Study. 2019 , 211, 34-44		12
165	Up-To-Date View on the Clinical Manifestations and Complications of Chronic Pancreatitis. 2019 ,		
164	Prevalence of Dyslipidemia and Goal Attainment with Lipid-Lowering Therapy: Insights from Thai Multicenter Study and Overview of the Major Guidelines. 2019 ,		
163	Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk. 2019 , 19, 146		4
162	Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients. 2019 , 11,		8
161	Prognostic Importance of Systemic Endotoxemia Indicators in Atherogenesis. 2019 , 45, 543-551		6
160	Management of Low Density Lipoprotein Cholesterol at a primary care diabetes clinic in Kuwait. 2019 , 13, 259-265		
159	Performance evaluation of 10-year ultrasound image-based stroke/cardiovascular (CV) risk calculator by comparing against ten conventional CV risk calculators: A diabetic study. 2019 , 105, 125-143		29
158	Dietary natural products as emerging lipoprotein(a)-lowering agents. 2019 , 234, 12581-12594		17
157	Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: an overview of systematic reviews. 2019 , 19, 11		15

156	Comparison of Recommendations and Use of Cardiovascular Risk Equations by Health Technology Assessment Agencies and Clinical Guidelines. 2019 , 22, 210-219	3
155	Food groups and risk of coronary heart disease, stroke and heart failure: A systematic review and dose-response meta-analysis of prospective studies. 2019 , 59, 1071-1090	236
154	Effect of pistachio on brachial artery diameter and flow-mediated dilatation: A systematic review and meta-analysis of randomized, controlled-feeding clinical studies. 2019 , 59, 328-335	9
153	Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : A meta-analysis of trials with East Asian populations. 2020 , 45, 594-602	4
152	Low-Density Lipoprotein Cholesterol Target Attainment in Patients Surviving an Acute Coronary Syndrome in Thailand: Results From the Dyslipidaemia International Study (DYSIS) II. 2020 , 29, 405-413	1
151	Carotid plaques and neurological impairment in patients with acute cerebral infarction. <i>PLoS ONE</i> , 2020 , 15, e0226961	3-7 5
150	Association of circulating selenium concentration with dyslipidemia: Results from the NHANES. 2020 , 58, 126438	15
149	The effects of an individualized health-risk report intervention on changes in perceived inactivity-related disease risk in adults with cerebral palsy. 2020 , 13, 100868	1
148	Artificial intelligence framework for predictive cardiovascular and stroke risk assessment models: A narrative review of integrated approaches using carotid ultrasound. 2020 , 126, 104043	15
147	Frailty status and cardiovascular disease risk profile in middle-aged and older females. 2020 , 140, 111061	2
146	Validation of 10-Year Stroke Prediction Scores in a Community-Based Cohort of Chinese Older Adults. 2020 , 11, 986	0
145	Associations between peroxisome proliferator-activated receptor α (PPAR- α) polymorphisms and serum lipids: Two cross-sectional studies of community-dwelling adults. 2020 , 762, 145019	2
144	Ultrasound-based stroke/cardiovascular risk stratification using Framingham Risk Score and ASCVD Risk Score based on "Integrated Vascular Age" instead of "Chronological Age": a multi-ethnic study of Asian Indian, Caucasian, and Japanese cohorts. 2020 , 10, 939-954	8
143	A 10-Year Risk of Cardiovascular Disease among Patients with Severe Mental Illness at Mbarara Regional Referral Hospital, Southwestern Uganda. 2020 , 2020, 2508751	3
142	Low-Density Lipoprotein Cholesterol and Adverse Cardiovascular Events After Percutaneous Coronary Intervention. 2020 , 76, 1440-1450	8
141	Cardiovascular/stroke risk predictive calculators: a comparison between statistical and machine learning models. 2020 , 10, 919-938	31
140	The role of the Mediterranean diet on weight loss and obesity-related diseases. 2020 , 21, 315-327	22
139	Strategies for enhancing the initiation of cholesterol lowering medication among patients at high cardiovascular disease risk: a qualitative descriptive exploration of patient and general practitioners' perspectives on a facilitated relay intervention in Alberta, Canada. 2020 , 10, e038469	1

138	Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months results. 2020 , 170, 108416		
137	Comparing the Effect of Combining Exercise with Rosuvastatin versus Atorvastatin on Lipid Profile and Functional Capacity: A Retrospective Cohort Study. 2020 , 2020, 7026530		0
136	Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry. 2020 , 76, 385-394		3
135	Wild rice (<i>Zizania</i> spp.): A review of its nutritional constituents, phytochemicals, antioxidant activities, and health-promoting effects. 2020 , 331, 127293		17
134	Nanoscale Technologies in Highly Sensitive Diagnosis of Cardiovascular Diseases. 2020 , 8, 531		7
133	Rate of dyslipidemia higher among women living with HIV: A comparison of metabolic and cardiovascular health in a cohort to study aging in HIV. 2020 , 21, 418-428		8
132	Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule. 2020 , 2020, 3491764		16
131	Dose-response analysis between hemoglobin A1c and risk of atrial fibrillation in patients with and without known diabetes. <i>PLoS ONE</i> , 2020 , 15, e0227262	3-7	5
130	Reduced risk of post ERCP pancreatitis in statin users. 2020 , 20, 125		3
129	Risk scoring for the primary prevention of cardiovascular disease. 2017 , 3, CD006887		45
128	Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial. 2021 , 24, 111-115		3
127	Comorbidity Management in Black Women Diagnosed with Breast Cancer: the Role of Primary Care in Shared Care. 2021 , 36, 138-146		2
126	Multiclass machine learning vs. conventional calculators for stroke/CVD risk assessment using carotid plaque predictors with coronary angiography scores as gold standard: a 500 participants study. 2021 , 37, 1171-1187		21
125	Bergamot phytosome improved visceral fat and plasma lipid profiles in overweight and obese class I subject with mild hypercholesterolemia: A randomized placebo controlled trial. 2021 , 35, 2045-2056		8
124	The role of the plasma glycosylated hemoglobin A1c/Apolipoprotein A-I ratio in predicting cardiovascular outcomes in acute coronary syndrome. 2021 , 31, 570-578		4
123	Coronary heart disease risk assessment among workers in a carbon black factory. 2021 , 57, 224-229		
122	Comparative risk assessment for the development of cardiovascular diseases in the Hungarian general and Roma population. 2021 , 11, 3085		5
121	Polypill in Persons without Cardiovascular Disease. 2021 , 384, 1673-1674		

120	Incorporation of biochemical parameters and diagnostic algorithms in the laboratory computer system for the early detection of lipid abnormalities from the lipid units. 2021 , 33, 273-281		
119	Attenuating the Variability of Lipids Is Beneficial for the Hypertension Management to Reduce the Cardiovascular Morbidity and Mortality in Older Adults. 2021 , 8, 692773		0
118	Impact of the 2016 Canadian Lipid Guidelines on Daily Practice at a Community Hospital. 2021 ,		
117	The effect of a 6-month ketogenic medium-chain triglyceride supplement on plasma cardiometabolic and inflammatory markers in mild cognitive impairment. 2021 , 169, 102236		5
116	7500 pas quotidiens ou 15 minutes d'activit� physique d'intensit� moyenne � intense: est-ce suffisant pour la pr� vention secondaire des cardiopathies isch� miques?. 2021 ,		
115	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 1129-1150	3.8	62
114	Glucose induced hepatic lipase expression and ApoB100/ApoAI ratio changes in cultured HepG2 cells in vitro. 10, 842		
113	British Columbia CARMA-CHIWOS Collaboration (BCC3): protocol for a community-collaborative cohort study examining healthy ageing with and for women living with HIV. 2021 , 11, e046558		0
112	Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real-world evidence study. 2021 , 44, 1613-1620		3
111	Laboratory reporting of framingham risk score increases statin prescriptions in at-risk patients. 2021 , 96, 1-7		0
110	The Priority of Non-HDL-C Assessment to Predict New Lesions among Stable Angina Patients with Strong Statins. 2021 ,		
109	Patterns of chronic disease management and health outcomes in a population-based cohort of Black women with breast cancer. 2021 , 32, 157-168		1
108	Medical Complications Resulting from Severe Obesity. 2017 , 49-73		2
107	Lifestyle Interventions for Primary and Secondary Prevention of Cardiovascular Disease. 2015 , 1695-1718		1
106	Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol . 2017 , 11, 1065-1072		29
105	The Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Adult Patients with Type 2 Diabetes: The Multicentre Randomized Controlled REACH Trial. 2017 , 41, 580-586		17
104	An integrated method of therapeutic lifestyle change for older adults with dyslipidaemia. 2017 , 148, 30-36		1
103	Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men. 2016 , 5, 852		4

102	Statins for primary cardiovascular prevention in the elderly. 2015 , 12, 431-8	24
101	2016 Chinese guidelines for the management of dyslipidemia in adults. 2018 , 15, 1-29	142
100	Glycemic Index and Diabetes Mellitus. 2016 , 45-77	1
99	Vital Signs: Predicted Heart Age and Racial Disparities in Heart Age Among U.S. Adults at the State Level. 2015 , 64, 950-8	21
98	The Role of Fructose, Sucrose and High-fructose Corn Syrup in Diabetes. 2014 , 10, 51-60	3
97	Re-assessing the role of non-fasting lipids; a change in perspective. 2016 , 4, 431	14
96	Statins and Elderly: From Clinical Trials to Daily Practice. 2019 , 17, 233-238	2
95	Fasting-Evoked En Route Hypoglycemia in Diabetes (FEEHD): From Guidelines to Clinical Practice. 2020 , 16, 949-956	2
94	Prognostic Assessment of Diabetics Using Myocardial Perfusion Imaging: Diabetes Mellitus is Still a Coronary Artery Disease Equivalent. 2017 , 11, 76-83	2
93	South Asian Heart Risk Assessment (SAHARA): Randomized Controlled Trial Design and Pilot Study. 2013 , 2, e33	10
92	Development of an Evidence-Informed Blog to Promote Healthy Eating Among Mothers: Use of the Intervention Mapping Protocol. 2017 , 6, e92	14
91	Integration of estimated glomerular filtration rate biomarker in image-based cardiovascular disease/stroke risk calculator: a south Asian-Indian diabetes cohort with moderate chronic kidney disease. 2020 , 39, 290-306	12
90	A Positive Association between a Western Dietary Pattern and High LDL-C among Iranian Population. 2020 , 20, e00485	3
89	Twelve-month prospective randomized study of pharmacists utilizing point-of-care testing for metabolic syndrome and related conditions in subjects prescribed antipsychotics. 2014 , 16,	9
88	Prevalence of Lipid Abnormalities and Cholesterol Target Value Attainment in Patients with Stable and Acute Coronary Heart Disease in the United Arab Emirates. 2019 , 20, 37-46	2
87	Awareness and use of cardiovascular risk scores by family physicians in southeastern Ontario. 2013 , 03, 487-490	3
86	Treatment Toxicity. 2021 , 291-308	
85	Coronary Artery Calcium. 2014 , 181-189	

- 84 Non-statin Therapies for CKD with Dyslipidemia. **2014**, 153-178
- 83 Dyslipidemias. **2014**, 1-11
- 82 Lipid-Lowering Drugs. **2014**, 1-19
- 81 Non-Immunosuppressant Medication Use in Heart Transplant Patients: A Guide for Pharmacists. **2014**, 05, 950-958
- 80 Lifestyle Interventions for Primary and Secondary Prevention of Cardiovascular Disease. **2014**, 1-29
- 79 Which One to Endorse Among the Multitude of Lipid Guidelines?. **2015**, 11, 32-33
- 78 Axonal, bladder and bowel impairment: evidence based clinical review of gaps in guidelines for spinal stenosis. **2015**, 25, 53-62
- 77 Association between LDL-C, Non HDL-C, and Apolipoprotein B Levels with Coronary Plaque Regression. **2015**, 105, 11-9 8
- 76 Composite Risk Scores. **2016**, 41-54
- 75 Vascular Disease in Young Indians (20-40 years): Role of Dyslipidemia. **2016**, 10, OE01-5 3
- 74 14. Familial hypercholesterolemia. **2016**, 243-266
- 73 Glycemic Index and Cardiovascular Disease Risk Prevention and Management. **2016**, 79-105
- 72 Non-pharmacological interventions for cardiovascular complications in patients with rheumatoid arthritis. **2017**, 93-106
- 71 HEAL for Heart Diseases. **2016**, 115-140
- 70 Cardiovascular Risk Stratification and Statin Eligibility Based on the Brazilian vs. North American Guidelines on Blood Cholesterol Management. **2017**, 108, 508-517 2
- 69 Updated Geriatric Cardiology Guidelines of the Brazilian Society of Cardiology - 2019. **2019**, 112, 649-705 5
- 68 Changes in Renal Disease: A Vascular Perspective. **2019**, 2, 89-94
- 67 Gut Mycobiome Dysbiosis Is Linked to Hypertriglyceridemia among Home Dwelling Elderly Danes. 2

66	Nutrition, metabolic syndrome, and obesity: Guidelines for the care of people with spina bifida. 2020 , 13, 637-653	1
65	HIV and Dyslipidemia. 2021 , 431-466	
64	Cardiovascular disease risk prediction for people with type 2 diabetes in a population-based cohort and in electronic health record data. 2020 , 3, 583-592	2
63	Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. 2013 , 59, 1169-80	35
62	Is diabetes a coronary artery disease equivalent?. 2013 , 59, 1306	
61	[Not Available]. 2014 , 67, 186-7	
60	Evolution of lipid management guidelines: evidence might set you free. 2014 , 60, 612-7, e333-9	
59	Break the fast? Update on patient preparation for cholesterol testing. 2014 , 60, 895-7, e471-4	6
58	Family history of cardiovascular disease. 2014 , 60, 1016	13
57	Frequency of Testing for Dyslipidemia: A Systematic Review and Budget Impact Analysis. 2014 , 14, 1-27	2
56	Frequency of Testing for Dyslipidemia: An Evidence-Based Analysis. 2014 , 14, 1-30	
55	Simplified lipid guidelines: Prevention and management of cardiovascular disease in primary care. 2015 , 61, 857-67, e439-50	29
54	Familial hypercholesterolemia: Review of diagnosis, screening, and treatment. 2016 , 62, 32-7	26
53	Update on age-appropriate preventive measures and screening for Canadian primary care providers. 2016 , 62, 131-8	14
52	Adult health checkup: Update on the Preventive Care Checklist Form* . 2016 , 62, 307-13	7
51	Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. 2017 , 63, e495-e503	16
50	Cardiovascular risk factor documentation and management in primary care electronic medical records among people with schizophrenia in Ontario, Canada: retrospective cohort study. 2020 , 10, e038013	
49	Cardiovascular risk profile and osteoarthritis - considering sex and multisite joint involvement: a CLSA population-based study. 2021 ,	0

- 48 Incorporation of biochemical parameters and diagnostic algorithms in the laboratory computer system for the early detection of lipid abnormalities from the lipid units. **2021**, 33, 273-273
- 47 Cardiovascular risk factor documentation and management in primary care electronic medical records among people with schizophrenia in Ontario, Canada: retrospective cohort study. **2020**, 10, e038013 ^o
- 46 Prescription profile of antiarrhythmic drugs in a group of patients in Colombia. **2021**, 35, 213-229
- 45 Glucose induced ApoB100/ApoAI ratio changes in cultured HepG2 cells in vitro. 10, 842
- 44 A Powerful Paradigm for Cardiovascular Risk Stratification Using Multiclass, Multi-Label, and Ensemble-Based Machine Learning Paradigms: A Narrative Review.. **2022**, 12, 3
- 43 Overweight and obese youth with type 1 or type 2 diabetes share similar elevation in triglycerides during middle and late adolescence.. **2022**, 16, 138-143 ^o
- 42 Image_1.TIF. **2018**,
- 41 Image_2.TIF. **2018**,
- 40 Image_3.TIF. **2018**,
- 39 Image_4.TIF. **2018**,
- 38 Image_5.TIF. **2018**,
- 37 Image_6.TIF. **2018**,
- 36 Image_7.TIF. **2018**,
- 35 Image_8.TIF. **2018**,
- 34 Image_9.TIF. **2018**,
- 33 Table_1.DOCX. **2018**,
- 32 Table_10.DOCX. **2018**,
- 31 Table_11.DOCX. **2018**,

30 Table_12.DOCX. 2018,

29 Table_13.DOCX. 2018,

28 Table_14.DOCX. 2018,

27 Table_15.DOCX. 2018,

26 Table_2.DOCX. 2018,

25 Table_3.DOCX. 2018,

24 Table_4.DOCX. 2018,

23 Table_5.DOCX. 2018,

22 Table_6.DOCX. 2018,

21 Table_7.DOCX. 2018,

20 Table_8.DOCX. 2018,

19 Table_9.DOCX. 2018,

18 Data_Sheet_1.doc. 2020,

17 Effects of aerobic and resistance exercise on glycosylated hemoglobin (HbA1c) concentrations in non-diabetic Taiwanese individuals based on the waist-hip ratio.. *PLoS ONE*, 2022, 17, e0267387 3-7

16 A novel method for vascular age estimation via pressure pulse wave of radial artery. *Biomedical Signal Processing and Control*, 2022, 78, 103904 4-9

15 The Global Burden of Diseases attributed to high low-density lipoprotein cholesterol from 1990 to 2019. 10,

14 Deep learning artificial intelligence framework for multiclass coronary artery disease prediction using combination of conventional risk factors, carotid ultrasound, and intraplaque neovascularization. 2022, 150, 106018 ○

13 The Association Between Vitamin D Levels and the 10-Year Risk of Atherosclerotic Cardiovascular Disease. Publish Ahead of Print, ○

12	Impact of processing on bioaccessibility of phytochemicals in nuts. 1-18	○
11	Effect of the interaction between alcohol and meat consumption on the hyperlipidaemia risk among elderly individuals: Evidence from Shanghai, China. 9,	○
10	Prevalence of Dyslipidemia among School-Age Children and Adolescents in Addis Ababa, Ethiopia.	○
9	Outpatient management of patients after surgical operations for acute aortic dissection of type A. 2022 , 19, 44-49	○
8	Vascular age acquired from the pulse signal: A new index to screen early vascular aging. 2022 , 151, 106355	○
7	Primary Care Clinical Volumes, Cholesterol Testing, and Cardiovascular Outcomes. 2022 ,	○
6	The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer. 2023 ,	○
5	Impact of prescription length supply policy on patient medication adherence in Thailand.	○
4	Association between obesity indicators and cardiometabolic disease in Chinese adults. 2023 , 18, e0273235	○
3	Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment. 2023 , 28, 969	1
2	Safety and Effectiveness of Evolocumab During Acute and Sub-acute Phases of Acute Coronary Syndrome (ACS): A Systematic Review and Meta-analysis. 2023 ,	○
1	Joint effect of whole blood metals exposure with dyslipidemia in representative U.S adults in NHANES 2011-2020.	○